JPRN-jRCTs061210087招募中2 期
phase II clinical trial of a therapeutic vaccine containing HBs/HBcAg for HBV carriers without ongoing anti-HBV treatment - HepBVac-P2ASC
Hiasa Yoichi0 个研究点目标入组 200 人开始时间: 2022年3月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •HBV carriers who fulfill the inclusion criteria below
- •(1) 20-85 years old
- •(2) Positive for HBsAg or HBV-DNA
- •(3) Not under nucleos(t)ide analogue or interferon treatment
- •(4) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS: 0-2)
- •(5) No evidence of organ dysfunction
- •Liver: Child-Pugh Score less than 9
- •Kidney: eGFR more than 30
- •Heart: No severe heart failure by interview
- •Lung: SpO2 above 90% in room air
排除标准
- •(1) Allergic history of past vaccination
- •(2) Pregnant, unwilling to practice contraception during the study or lactating female
- •(3) Severe complication (malignant hypertension, severe congestive heart failure, severe liver failure, poorly controlled diabetes mellitus, severe pulmonary fibrosis, active interstitial pneumonia)
- •(4) Bearing malignant carcinoma including HCC
- •(5) Severe mental disability
- •(6) Positive for HCV-RNA
- •(7) Taking immunosuppressive drugs, steroid, interferon prior 90 days
- •(8) Taking nucleos(t)ide analogues
- •(9) Inappropriate to participate in this trial
研究者
相似试验
招募中
2 期
Clinical trial of therapeutic vaccine against chronic hepatitis B patients under NAs treatmentchronic hepatitis BJPRN-jRCTs061210086Hiasa Yoichi140
进行中（未招募）
1 期
oGlioblastoma is the most common primary brain tumour in humans withthe most severe prognosis. Standard treatments consist primarily ofsurgery in order to debulk thetumoral mass, as well asradiochemotherapy to induce optimal local tumor control. However themedian overall survival (OS)is about 15 months, with 88% of patientsdead within 3 yearsMedDRA version: 18.0Level: HLTClassification code 10045172Term: Tumour vaccine therapiesSystem Organ Class: 100000004865EUCTR2013-005387-25-ITSapienza, University of Rome10
进行中（未招募）
不适用
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.EUCTR2010-018770-20-NOOslo University Hospital30
尚未招募
1 期
Herpes Zoster Vaccine for Bone Marrow Transplant donorsVaricella zoster in immunsuppressed stem cell transplant recipientsInfection - Other infectious diseasesInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12611000640909MERCK SHARP & DOHME20
进行中（未招募）
1 期
Study to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphismsMetastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001508-45-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)100